![]() |
Name |
4,6-Dihydroxy-5-methoxy-7-methylphthalide
|
Molecular Formula | C10H10O5 | |
IUPAC Name* |
4,6-dihydroxy-5-methoxy-7-methyl-3H-2-benzofuran-1-one
|
|
SMILES |
CC1=C2C(=C(C(=C1O)OC)O)COC2=O
|
|
InChI |
InChI=1S/C10H10O5/c1-4-6-5(3-15-10(6)13)8(12)9(14-2)7(4)11/h11-12H,3H2,1-2H3
|
|
InChIKey |
ZCHKRHAJKBXPND-UHFFFAOYSA-N
|
|
Synonyms |
4,6-dihydroxy-5-methoxy-7-methylphthalide
|
|
CAS | NA | |
PubChem CID | 50991408 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 210.18 | ALogp: | 1.0 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 76.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 15 | QED Weighted: | 0.687 |
Caco-2 Permeability: | -4.925 | MDCK Permeability: | 0.00001640 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.014 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.351 | Plasma Protein Binding (PPB): | 90.18% |
Volume Distribution (VD): | 0.767 | Fu: | 8.61% |
CYP1A2-inhibitor: | 0.862 | CYP1A2-substrate: | 0.931 |
CYP2C19-inhibitor: | 0.047 | CYP2C19-substrate: | 0.532 |
CYP2C9-inhibitor: | 0.07 | CYP2C9-substrate: | 0.649 |
CYP2D6-inhibitor: | 0.05 | CYP2D6-substrate: | 0.271 |
CYP3A4-inhibitor: | 0.067 | CYP3A4-substrate: | 0.171 |
Clearance (CL): | 13.088 | Half-life (T1/2): | 0.912 |
hERG Blockers: | 0.055 | Human Hepatotoxicity (H-HT): | 0.054 |
Drug-inuced Liver Injury (DILI): | 0.443 | AMES Toxicity: | 0.658 |
Rat Oral Acute Toxicity: | 0.119 | Maximum Recommended Daily Dose: | 0.051 |
Skin Sensitization: | 0.532 | Carcinogencity: | 0.124 |
Eye Corrosion: | 0.043 | Eye Irritation: | 0.924 |
Respiratory Toxicity: | 0.223 |